• Nuclear Medicine and Molecular Imaging
• /
• 제43권4호
• /
• pp.344-351
• /
• 2009

목적: 광학영상기술은 소동물이나 임상연구에서 분자영상법으로 알려진 첨단연구 분야이다. 광학영상기기는 소동물영상연구 및 추적연구에 중요한 역할을 수행하고 있다. 발광영상에서 소동물을 영상화 하기 위해서는 피부조직을 뚫고 나오는 광자를 검출하기 위한 고민감도 CCD카메라가 필요하다. 이 연구에서는 소동물에서 발생하는 발광신호를 검출하기 위해 개발한 광학영상기기를 소개하고자 한다. 대상 및 방법: 냉각형 CCD카메라와 집광렌즈, 8개의 백색광 LED광원을 암실상자 안에 장치하였다. 팬텀 및 튜브를 이용한 영상을 얻은 후 발광 박테리아를 이용하여 CT26 암모델 누드마우스에서 영상을 획득하였다. 결과: 발광영상을 얻기 위한 광학영상기기를 설계하고 개발하였다. 영상획득이 성공적으로 수행되었고, 시스템을 완성하였다. 개발된 장비는 분자영상연구에 사용되고 있다. 결론 개발된 광학영상장비는 다양한 실험적 조건을 만족하는 연구에 최적화하여 유용한 도구로 자리잡을 것으로 기대한다.

• 대한방사성의약품학회지
• /
• 제8권2호
• /
• pp.103-111
• /
• 2022

Idiopathic pulmonary fibrosis (IPF) is a progressive disease caused by some risk factors, including smoking, viral infection, toxic substances, and radiation, that decline lung function of fresh oxygen and blood delivery throughout the body. Patients with pulmonary fibrosis have suffered from breathing and cough and the average survival rate is only 3 years after diagnosis. Therefore, it is significant to diagnose IPF and start treatment in enough time. Usually, lung biopsy is available to diagnose localized pulmonary fibrotic sites directly. However, it is insufficient to visualize whole lung tissue, and also it has a risk of infection for patients. In the clinic, medical imaging systems can diagnose pulmonary fibrosis non-invasively without infection. In this review, we introduce current medical imaging systems used to diagnose pulmonary fibrosis, including CT, MRI, and nuclear medicine. Further, we introduce several molecular imaging probes targeting specific biomarkers which are expressed in pulmonary fibrosis. Through this paper, it is expected that it would be helpful to understand the latest knowledge and research trends on pulmonary fibrosis diagnostic imaging.

• Nuclear Engineering and Technology
• /
• 제54권7호
• /
• pp.2592-2598
• /
• 2022

Research groups in the field of PET instrumentation are studying time-of-flight(TOF) technology to improve the signal-to-noise ratio of PET images. Scintillation light transport and collection plays an important role in improving the coincidence resolving time(CRT) of PET detector based on a pixelated crystal array. Four crystal arrays were designed by the different optical reflection configuration such as external reflectors and surface treatment on the CRT and compared with the light output, energy resolution and CRT. The design proposed in the study was composed of 8 × 8 LYSO crystal array consisted of 3 × 3 × 15 mm³ pixels. The entrance side was roughened while the other five surfaces were polished. Four sides of all crystal pixels were wrapped with ESR-film, and the entrance surface was covered by Teflon-tape. The design provided an excellent timing resolution of 210 ps and improved the CRT by 16% compared to the conventional method using a polishing treatment and ESR-film. This study provided a method for improving the light output and CRT of a pixelated scintillation crystal-based brain TOF PET detector. The proposed configuration might be an attractive detector design for TOF brain PET requiring fast timing performance with high cost-effectiveness.

• 한국정보디스플레이학회:학술대회논문집
• /
• 한국정보디스플레이학회 2004년도 Asia Display / IMID 04
• /
• pp.812-815
• /
• 2004

The molecular structure influences the thermal behavior of HTM. For OLED the glass transition temperature and evaporation temperature are critical. We report how changes in structure cause changes on both parameters. The results may be of interest for chemists when they design new molecule structures for OLED.

• 대한약리학회:학술대회논문집
• /
• 대한약리학회 2006년도 58th Annual Meeting of The Korean Society of Pharmacology
• /
• pp.54-54
• /
• 2006

• 대한방사성의약품학회지
• /
• 제1권1호
• /
• pp.23-30
• /
• 2015

Radioisotopes emitting low-range highly ionizing radiation such as ${\beta}$-particles are of increasing significance in internal radiotherapy. Among the ${\beta}$-particle emitting radioisotopes, $^{67}Cu$ is an attractive radioisotope for various nuclear medicine applications due to its medium energy ${\beta}$-particle, gamma emissions, and 61.83-hour half-life, which can also be used with $^{64}Cu$ for PET imaging. The production and application of the ${\beta}$-emitting radioisotope $^{67}Cu$ for therapeutic radiopharmaceutical are outlined, and different production routes are discussed. A survey of copper chelators used for antibody labeling is provided. It has been produced via proton, alpha, neutron, and gamma irradiations followed by solvent extraction, ion exchange, electrodeposition. Clinical studies using $^{67}Cu$-labelled antibodies in lymphoma, colon carcinoma and bladder cancer patients are reviewed. Widespread use of this isotope for clinical studies and preliminary treatments has been limited by unreliable supplies, cost, and difficulty in obtaining therapeutic quantities.

• 대한방사성의약품학회지
• /
• 제1권1호
• /
• pp.1-8
• /
• 2015

It is essential use of long term half life radioisotopes for positron emission tomography (PET) imaging study of biopharmaceuticals because most of biopharmaceuticals have long biological half-life. Some representative isotopes are $^{124}I$, $^{64}Cu$, $^{89}Zr$ and so on. These PET radioisotopes and their radiopharmaceuticals have recently received growing interest because of long half life and good imaging properties. Furthermore, $^{64}Cu$ and $^{89}Zr$ can be used in a number of radiopharmaceuticals due to its ease of conjugation to peptides and antibodies using the proper chelator. In recent years, since $^{124}I$ was first developed in 2005, we have been studied to develop an efficient method and procedure for producing these radioisotopes, and we have made considerable progress in production of long term half life radioisotopes. This review introduces the general production system, purification procedure, and several advances on targeting method for $^{124}I$ and $^{64}Cu$ in KIRAMS.

• Nuclear Engineering and Technology
• /
• 제48권3호
• /
• pp.597-607
• /
• 2016

Personalized medicine is tailored medical treatment that targets the individual characteristics of each patient. Theragnosis, combining diagnosis and therapy, plays an important role in selecting appropriate patients. Noninvasive in vivo imaging can trace small molecules, antibodies, peptides, nanoparticles, and cells in the body. Recently, imaging methods have been able to reveal molecular events in cells and tissues. Molecular imaging is useful not only for clinical studies but also for developing new drugs and new treatment modalities. Preclinical and early clinical molecular imaging shows biodistribution, pharmacokinetics, mechanisms of action, and efficacy. When therapeutic materials are labeled using radioisotopes, nuclear imaging with positron emission tomography or gamma camera can be used to treat diseases and monitor therapy simultaneously. Such nuclear medicine technology is defined as radiation theragnosis. We review the current development of drugs and technology for radiation theragnosis using peptides, albumin, nanoparticles, and cells.

• 대한핵의학회지
• /
• 제38권2호
• /
• pp.143-151
• /
• 2004

Recent progress in the development of non-invasive imaging technologies continues to strengthen the role of molecular imaging biological research. These tools have been validated recently in variety of research models, and have been shown to provide continuous quantitative monitoring of the location(s), magnitude, and time-variation of gene expression. This article reviews the principles, characteristics, categories and the use of radionuclide reporter gene imaging technologies as they have been used in imaging cell trafficking, imaging gene therapy, imaging endogenous gene expression and imaging molecular interactions. The studios published to date demonstrate that reporter gene imaging technologies will help to accelerate pre-clinical model validation as well as allow for clinical monitoring of human diseases.

• 대한핵의학회지
• /
• 제38권2호
• /
• pp.140-142
• /
• 2004

As a molecular imaging is the most up-to-date technology in Nuclear Medicine, it has complicate ethical and regulatory problems. For animal experiment, we have to follow institutional animal care committee. for clinical experiment, we have to get approval of Institutional Review Board according to Helsinki declaration. In addition, approval from Korea Food and Drug Administration (KFDA) is essential for manufacturing and commercialization. However, too much regulation would suppress development of new technology, which would result in the loss of national competitive power. In addition, most new radioactive ligands for molecular imaging are administered to human at sub-pharmacological and sub-toxicological level. In conclusion, a balanced regulation is essential for the safety of clinical application and development of new technology.